Skip to main content

Select Drug Profiles

Practice Management
Comparing the Medicaid Retrospective Drug Utilization Review Program Cost-Savings Methods Used by State Agencies
Sergio I. Prada, MPA, PhD
Sergio I. Prada, MPA, PhD
Stakeholder Perspective
Is the Federal Drug Utilization Review Requirement Just Red Tape or an Enlightened State of Flexibility?
Michael Kleinrock
by Michael Kleinrock
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naïve Patients with CLL: The Phase 1b/2 ACE-CL-003 Study
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Adverse Events, Resource Use, and Economic Burden in Patients with Mantle-Cell Lymphoma in the United States
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
High Complete Response Rates with Pembrolizumab with Rituximab in Patients with Relapsed FL: Results of an Open-Label, Phase 2 Study
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Efficacy and Safety of Bendamustine and Rituximab as First Salvage Treatment in CLL: Results of the GIMEMA-ERIC LLC1315 Study
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Phase 1/2 Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Randomized Trial of Ibrutinib versus Ibrutinib plus Rituximab in Patients with CLL
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Combined Venetoclax and Ibrutinib for Patients with Previously Untreated, High-Risk CLL and Relapsed/Refractory CLL: A Phase 2 Trial
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
A Multicenter, Phase 2 Study of Ibrutinib plus FCR as Frontline Therapy for Younger Patients with CLL
Read More
Page 77 of 244
Results 761 - 770 of 2438